Nov 14, 2022 / 04:00AM GMT
Operator
Good morning, ladies and gentlemen, welcome to the Q2 FY '23 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Utkarsh Gandhi -
Thank you, moderator. Good morning, everyone, and a very warm welcome to the Q2 FY '23 results conference call of Glenmark Pharmaceuticals Limited. Before we start the call, a quick review of the operations for the company for the quarter ended September 30, 2022. For the second quarter of FY '23, Glenmark's consolidated revenue from operations was at INR 33,752 million, as against INR 31,474 million in the corresponding quarter last year, recording a growth of 7.2%. For the 6 months ended September 30, 2022, Glenmark's consolidated revenue was at INR 61,525 million as against INR 61,123 million, recording an increase of 0.7%.
We'll provide some key highlights for each of our businesses,
Q2 2023 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Nov 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers